Biotech for the rest of the world
23 November, 2005 by Susan WilliamsonThe latest medical technology is all very well - if you can afford it. Susan Williamson looks at how one Australian group is coming up with practical healthcare solutions for the developing world.
Cancer breakthrough for UQ researchers
16 November, 2005 by Graeme O'NeillUniversity of Queensland researchers have reported spectacular success in killing cervical cancer cells and preventing the cancer in female mice, using RNA-interference (RNAi) therapy.
Rockeby shares soar after bird flu test deal
08 November, 2005 by Ruth BeranShares in Rockeby Biomed (ASX:RBY) quadrupled in value today after the company announced it has signed a deal with Thailand-based Pacific Biotech for the exclusive marketing and distribution rights in Europe, the Asia-Pacific and South Africa to two tests for avian flu.
Prana pleased with Alzheimer's trial results
07 November, 2005 by Graeme O'NeillPrana Biotech (ASX:PBT, NASDAQ:PRAN) announced today that its candidate PBT2 therapy for Alzheimer's disease has come through a phase I single-dose escalation trial in the Netherlands, with a superior pharmacokinetic profile to its predecessor, clioquinol.
Resonance expands into liver fibrosis
04 November, 2005 by Helen SchullerPerth-based Resonance Health Group (ASX:RHT) will progress to being a "two-product company" with the commercialisation of a new test for liver fibrosis, the company's managing director said this week.
Probiomics launches share purchase plan
04 November, 2005 by Ruth BeranProbiomics (ASX:PCC), formerly VRI BioMedical, has launched a share purchase plan (SPP) which could raise AUD$2 million if fully subscribed.
WEHI to double in size under expansion plans
04 November, 2005 by Graeme O'NeillThe Victorian government has presented a birthday gift for Melbourne's Walter and Eliza Hall Institute for Medical Research: a AUD$50 million contribution towards the cost of a new seven-storey wing that will double the institute's size.
NZ company BrainZ to list on ASX in December
02 November, 2005 by Helen SchullerNew Zealand medical device company BrainZ Instruments, which develops monitors for the detection of brain injury, has lodged a prospectus for an IPO to raise up to AUD$13 million on the ASX.
Life Therapeutics signs US bioterror contract
01 November, 2005 by Helen SchullerSydney-based Life Therapeutics (ASX:LFE) has been awarded a contract worth US$4.7 million (AUD$6.29 million) to supply specialty plasma for the treatment and prevention of smallpox in the general population, and to counter bioterrorism.
Domantis lung study nets 'exciting' results
27 October, 2005 by Graeme O'NeillUK human domain-antibody (dAb) developer Domantis has reported spectacular success in trial of an inhaled anti-inflammatory dAB in an in vivo model of chronic obstructive pulmonary disorder (COPD).
Phylogica and Sunshine Heart net grants
26 October, 2005 by Helen SchullerDrug developer Phylogica (ASX:PYC) and artificial heart company Sunshine Heart (ASX:SHC) have been awarded a Commercial Ready grants from AusIndustry, worth $2.27 million and $2.223 million respectively.
Monash team determines cancer protein form
25 October, 2005 by Graeme O'NeillMonash University researchers have determined the structure of a key oncoprotein, JAK2, being targeted by Melbourne oncology drug developer Cytopia (ASX:CYT).
Phospha E linked to healthy cardiovascular function
21 October, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has found its vitamin product Phospha E has reduced LDL-C (bad cholesterol) concentrations in blood by up to 44 per cent in an animal study.
Apollo starts psoriasis trial
20 October, 2005 by Helen SchullerSydney-based biopharma Apollo Life Sciences (ASX:AOP) has commenced its phase Ib clinical trial for a topical psoriasis treatment, developed from human-expressed protein.
Panvax signs agreement with US institute to develop malaria vaccine
18 October, 2005 by Graeme O'NeillMelbourne's Austin Research Institute (ARI) and vaccine developer Panvax have signed an agreement with the Walter Reed Army Institute of Research to develop an experimental malaria vaccine.
